我国创新药企被提专利无效请求风险预警研究

朱雪忠; 李艳

PDF(360 KB)

科研管理 ›› 2021, Vol. 42 ›› Issue (7) : 22-30.

论文

我国创新药企被提专利无效请求风险预警研究

朱雪忠^1,2,李艳¹

作者信息 +

A research on the risk early-warning of patent invalidation requests of innovative pharmaceutical enterprises in China

Zhu Xuezhong^1,2, Li Yan¹

Author information +

文章历史 +

摘要

我国正由仿制药大国向创新药大国加速转型，越来越多的企业由仿制药企业向创新药企业转变。新角色下被提专利权无效宣告请求的风险日益升高，对企业专利管理实践提出新挑战。首次将我国原国家食品药品监督管理总局药品审评中心发布的《中国上市药品目录集》中创新药企业信息，与国家知识产权局专利局复审和无效审理部公布的专利权无效宣告请求案件信息链接。基于法律纠纷理论模型框架，实证分析药品发明专利无效请求发生概率的影响因素。研究表明：专利价值越高、专利法律质量越低、信息不对称程度（或当事人对无效结果的期望分歧）越大，被提无效请求的风险越高。与理论分析不一致的是，与制剂/组合物专利相比，药用化合物和药用生物分子专利被提无效请求的概率更低。研究结论为企业有效开展药品发明专利被提无效请求的风险预警提供有益借鉴。

Abstract

China is accelerating its transformation from a big country of generic drugs to a big country of innovative drugs, and more and more enterprises are transforming from generic pharmaceutical enterprises to innovative pharmaceutical enterprises. Under the new role, the risk of drug patent invalidation requests is increasing day by day, which poses a new challenge to the enterprise patent management practice. Patents are relied upon more frequently to protect pharmaceutical innovation. The cost of engaging in invalidation over issued drug patents diminishes their value as an incentive to invest in new drug R&D. From the perspective of enterprises, it is of great theoretical value and practical significance to study how to effectively carry out the early warning of the risk of drug patent invalidation requests.
In this paper, we examine the characteristics of drug patents involved in invalidation requests and their owners by combining, for the first time, information about"Catalogue of Chinese listed drugs"issued by China Food and Drug Administration (CFDA) with detailed data of case filings from Reexamination and Invalidation Department of the China Patent Office. By comparing filed cases to a control group, we show that there is substantial variation across patents in their exposure to risk of invalidation requests. We use this empirical evidence to examine hypotheses about the determinants of requests for invalidating drug patents. We show empirically that the risk increases with patent value , asymmetric information (or diverging expectations of invalidation outcomes) and low legal quality. In contrast to the theoretical predictions, the empirical findings suggest that formulation patent is challenged more frequently than composition of matter patent.
The possible contributions of this paper are as follows: Firstly, it expands and complements the previous studies on the determinants of the probability of occurrence of patent validity challenges, which mainly focus on patent invalidation proceedings in the United States and patent oppositions in the European Patent Office. Secondly, on the theoretical level, it takes the drug invention patent type as the index to measure the patent value from the dimension of protection scope/intensity, reveals the phenomenon that is inconsistent with the theoretical prediction under the actual national conditions, and enriches the understanding of the determinants of the probability of occurrence of patent validity challenges. Finally, at the practical level, it provides empirical evidence and useful reference for Chinese innovative drug enterprises. It is suggested that the ability to associate observable characteristics of drug patents to requests for invalidation risk should be exploited in developing forecasting tools, a classified management system should be established according to risk grade. "Patent invalidation insurance" can be insured for important pharmaceutical invention patents with high risk of request for invalidation. Early-warning of potential requests for invalidation risk of pharmaceutical invention patents is helpful to improve the patent management level of Chinese innovative pharmaceutical enterprises.
In addition, great importance should be attached to the writing quality of patent application documents including the specification, so as to improve the quality of patent law from the source. Chinese pharmaceutical enterprises still need to further strengthen the innovation of key technologies such as pharmaceutical compounds and medicinal biomolecules.

导出引用

朱雪忠李艳. 我国创新药企被提专利无效请求风险预警研究[J]. 科研管理. 2021, 42(7): 22-30

Zhu Xuezhong, Li Yan. A research on the risk early-warning of patent invalidation requests of innovative pharmaceutical enterprises in China[J]. Science Research Management. 2021, 42(7): 22-30

参考文献

[1] Arrow K J.The Economic Implication of Learning by Doing[J].The Review of Economic Studies,1962,29(3):155-173.

[2] 杨世民. 药事管理与法规[M].北京：高等教育出版社，2010.

Yang Shimin. Pharmacy Administration and Law[M].Beijing：Higher Education Press,2010.

[3] 胡明东. 生物医药大时代[M].北京：社会科学文献出版社，2019.

Hu Mingdong. The global era of Bio-pharmaceutical[M]. Beijing：Social Sciences Academic Press（China）, 2019.

[4] Melissa A. Schilling.Strategic Management of Technological Innovation[M]. New York：McGraw-Hill/Irwin, 2016.

[5] Mansfield, Edwin. Patents and Innovation: An Empirical Study[J]. Management Science, 1986, 32(2):173-181.

[6] 张米尔,李海鹏,国伟.国别专利制度下的专利产出和权利人差异研究[J].科学学研究,2019,37(12):2141-2148+2240.

Zhang Mier,Li Haipeng,Guo Wei. Research on institutional entrepreneurship of internet platform enterprises from institutional field transition perspective[J]. Studies in Science of Science, 2019,37(12):2141-2148+2240.

[7] 毛昊, 刘夏. 成本效率视角下中国专利无效制度的目标阐述与优化路径[C]. 第二届中国知识产权政策与管理发展论坛，2019：426-439.

Mao Hao，Liu Xia. On the goal and optimization path of China's patent invalidation system from the perspective of cost efficiency[C]. The Second China Intellectual Property Policy and Management Forum，2019:426-439.

[8] 陶凤波. 专利复审与无效代理实务[M]. 北京：知识产权出版社，2013.

Tao Fengbo. Patent reexamination and invalidation agency practice[M].Beijing：Intellectual Property Press，2013.

[9] Schankerman L M. Characteristics of Patent Litigation: A Window on Competition[J]. The RAND Journal of Economics, 2001, 32(1):129-151.

[10] Harhoff D, Reitzig M. Determinants of opposition against EPO patent grants—the case of biotechnology and pharmaceuticals[J]. International Journal of Industrial Organization, 2004, 22(4): 443-480.

[11] Cédric Schneider. The battle for patent rights in plant biotechnology: evidence from opposition fillings[J]. The Journal of Technology Transfer, 2011, 36(5):565-579.

[12] Caviggioli F, Scellato G, Ughetto E. International patent disputes: Evidence from oppositions at the European Patent Office[J]. Research Policy, 2013, 42(9):1634-1646.

[13] Sterlacchini, Alessandro. Patent oppositions and opposition outcomes: evidence from domestic appliance companies[J]. European Journal of Law and Economics, 2016, 41(1):183-203.

[14] Kapoor R, Karvonen M, Mohan A, et al. Patent citations as determinants of grant and opposition: case of European wind power industry[J]. Technology Analysis & Strategic Management, 2016, 28(8):950-964.

[15] Galasso A, Schankerman M. Patents and Cumulative Innovation: Causal Evidence from the Courts [J]. The Quarterly Journal of Economics,2015,130(1):317-369.

[16] Galasso A, Schankerman M. Patent rights, innovation, and firm exit[J]. The RAND Journal of Economics, 2018, 49(1):64-86.

[17] Gaessler F, Harhoff D, Sorg S. Patents and Cumulative Innovation – Evidence from Post-Grant Patent Oppositions[J]. Academy of Management Annual Meeting Proceedings, 2017, 2017(1):12800.

[18] Nagler M, Sorg S. The disciplinary effect of post-grant review – Causal evidence from European patent opposition[J]. Research Policy,2020,49(3): 103915.

[19] 张米尔, 国伟, 曲宁. 面向专利预警的专利申请关键特征研究[J]. 科研管理, 2018, 039(001):135-142.

Zhang Mier, Guo Wei, Qu Ning. A study of key features of patent application oriented to patent early-warning [J].Science Research Management, 2018, 039(001):135-142.

[20] 邓洁,余翔,崔利刚.基于专利信息的我国发明专利无效行为实证研究[J].情报杂志,2014,33(08):52-58.

Deng Jie,Yu Xiang, Cui Ligang. An Empirical Study on Invention Patent Invalidation Behavior in China Based on Patent Information [J].Journal of Intelligence,2014,33(08):52-58.

[21] 刘立春, 漆苏.专利特征对药品专利法律质量评估的实证研究[J]. 科研管理, 2015, 36(6):119-127.

Liu Lichun, Qi Su. A research on evaluating the legal quality of pharmaceutical patents by patent characteristics[J]. Science Research Management, 2015, 36(6):119-127.

[22] 刘佩佩，袁红梅. 专利权无效宣告结果的影响因素探讨——基于药物专利属性的实证研究[J]. 情报学报, 2017，036(04):66-74.

Liu PeiPei，Yuan HongMei.The Influential Factors of The Result of Patent Right Invalid Declaration-An Empirical Analysis Based on Pharmacy Patent Attributes[J].Journal of the China Society for Scientific and Technical Information, 2017，036 (04):66-74.

[23] 刘立春.二元专利质量研究[J].情报杂志,2017,36(11):168-174.

Liu Lichun.Research on Binary Patent Quality[J]. Journal of Intelligence, 2017,36(11):168-174.

[24] Priest G L, Klein B. The Selection of Dispute for Litigation[J]. The Journal of Legal Studies, 1984, 13(1):1-56.

[25] Cooter R D, Rubinfeld D L. Economic analysis of legal disputes and their resolution[J]. Journal of Economic Literature, 1989,27(3), 1067-1097.

[26] Manuel Trajtenberg. A Penny for Your Quotes: Patent Citations and the Value of Innovations[J]. The RAND Journal of Economicsn,1990,21(1):172-187.

[27] Jean O. Lanjouw,Ariel Pakes,Jonathan Putnam. How to Count Patents and Value Intellectual Property:The Uses of Patent Renewal and Application Data[J]. Journal of Industrial Economics,1998,46(4)：405–433.

[28] 万小丽, 朱雪忠. 专利价值的评估指标体系及模糊综合评价[J]. 科研管理, 2008, 029(2):185-191.

Wan Xiaoli, Zhu Xuezhong. The indicator system and fuzzy comprehensive evaluation of patent value[J]. Science Research Management, 2008, 029(2):185-191.

[29] 文庭孝. 专利信息计量学[M]. 北京：科学出版社，2017.

Wen Tingxiao. Patentometrics[M]. Beijing：Science Press，2017.

[30] Ellery T , Hansen N . Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand[M]. 2014.

[31] 张清奎. 医药及生物技术领域知识产权战略实务[M]. 北京：知识产权出版社, 2008.

Zhang Qingkui. Practice of Intellectual Property Strategy in Medicine and Biotechnology

[M].Beijing：Intellectual Property Press，2008.

[32] 乔永忠. 不同类型创新主体发明专利维持信息实证研究[J]. 科学学研究, 2011, 29(3):442-447.

Qiao Yongzhong. Empirical analysis of patent maintenance information of the different types of innovation subjects[J]. Studies in Science of Science, 2011, 29(3):442-447.

[33] 宋河发, 穆荣平, 陈芳.专利质量及其测度方法与测度指标体系研究[J].科学学与科学技术管理, 2010, 31 (4) :21-27.

Song Hefa,Mu Rongping,Chen Fang.Study on the Patent Quality and It's Measurement Index System[J]. Science of Science and Management of Science & Technology, 2010, 31 (4) :21-27.

[34] 施晴,王芸.基于专利转化的高校生物医药专利质量评价研究[J].科技管理研究,2019,39(11):139-145.

Shi Qing,Wang Yun. Quality Evaluation of Biomedical Patents Based on Colleges and Universities Patent Transformation[J].Science and Technology Management Research,

2019,39(11):139-145.

[35] 吴明隆. 问卷统计分析实务:SPSS操作与应用[M]. 重庆：重庆大学出版社, 2010.

Wu Minglong. Statistical analysis for questionnaire: operation and use of SPSS[M]. Chongqing: Chongqing University Press,2010．

[36] 何晓群, 闵素芹. 实用回归分析（第二版） [M]. 北京：高等教育出版社, 2014.

He Xiaoqun, Min Suqin. Applying regression analysis (2nd Edition) [M]. Beijing：Higher Education Press,2014.

[37] 陈强. 高级计量经济学及Stata应用（第二版）[M]. 北京：高等教育出版社, 2014.

Chen Qiang. Advanced econometrics and Stata application (2nd Edition) [M]. Beijing：Higher Education Press,2014.

[38] 丁锦希. 创新药物研发政策解读与战略管理[M]. 南京：江苏科学技术出版社, 2012.

Ding Jinxi. Policy Interpretation and Strategic Management of Innovation Drug R&D[M]. Nanjing：Phoenix Science Press, 2012.

[39] 吴志鹏, 方伟珠, 包海波. 专利制度对技术创新激励机制微观安排的三个维度[J]. 科学学与科学技术管理, 2003，024(001):52-56.

Wu Zhipeng，Fang Weizhu，BaoHaibo. Economic Analysis of the Microscopic Arrangement of Patent System for Technical Innovation [J]. Science of Science and Management of Science & Technology, 2003, 024(001):52-56.

[40] 宋燕,胡元佳,卞鹰. 药品技术价值与经济价值的相关性分析[J]. 中国药房, 2011，22(13):7-9.

Song Yan，Hu Yuanjia，Bian Ying. Correlation Between the Technical Value and the Economic Value of Drugs[J].China Pharmacy, 2011,22(13):7-9.